Explore Our Hematology History

Learn more about Roche commitment in pursuing longer, healthier lives for patients with blood diseases. Here you can discover how combining three decades of expertise with scientific curiosity and ambition, Roche seeks to address community needs.

Scientific expertise

With over 20 years of experience, our knowledge of hematology runs deep.

Our approved medicines have contributed greatly to advancing the treatment of different blood disorders, such as non-Hodgkin lymphoma, and several of our medicines are considered the standard-of-care in their approved indications.

Now we are developing innovative antibody therapies, by integrating novel immunotherapeutic approaches into our hematology clinical development programmes, including antibody-drug conjugate and bispecific antibodies.

We are expanding our capabilities in rare diseases like Hemophilia A and Paroxysmal Nocturnal Hemoglobinuria with novel classes of medicines.

We are exploring new disease areas, researching for new molecules and combinations for the treatment of Acute Myeloid Leukemia, Myelodysplastic Syndromes and Multiple Myeloma.


Advancing patient care

We help people with blood disorders live longer, healthier lives.

The breadth of our portfolio of medicines and our pipeline provides unique opportunity to develop regimens that combine different mechanisms of action, and target different synergistic pathways, which may enhance the benefits of our innovative medicines even further.

Our innovation goes beyond new modalities, and includes exploring new clinical trial designs, the use of surrogate endpoints and novel biomarkers, and improving the administration of our therapies.

Personalised healthcare is a core part of our vision, as we believe that more personalised approaches can transform patients’ lives by helping to prevent, diagnose and treat patients more effectively and quickly.


Innovation through collaboration

We forge meaningful partnerships and support sustainable access to our medicines, so we can help as many patients as possible.

Successful partnerships advance our innovative solutions.

We extend our efforts beyond the core clinical development programme to build long-standing relationships with patient advocacy groups.

Achieving our goals is only possible by partnering with patients, healthcare providers, payors, and health authorities.